Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: A retrospective, cross-sectional study

9Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications. Methods: Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing. Results: Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time. Conclusion: Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.

Cite

CITATION STYLE

APA

Tonozzi, T. R., Braunstein, G. D., Kammesheidt, A., Curran, C., Golshan, S., & Kelsoe, J. (2018). Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: A retrospective, cross-sectional study. Pharmacogenomics, 19(15), 1169–1179. https://doi.org/10.2217/pgs-2018-0088

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free